SOURCE: BioMedReports


February 05, 2010 15:59 ET

Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer

LOS ANGELES, CA--(Marketwire - February 5, 2010) - BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Keryx Biopharmaceuticals (NASDAQ: KERX) was mentioned in a published article which contained an inaccurate statement regarding the design of a pending Phase III study for patients with metastatic colorectal cancer.

Keryx CEO Ron Bentsur spoke to BioMedReports and has noted on record that it is estimated that approximately 50% to 60% of mCRC patients are KRAS positive, so that only this sub-group would potentially benefit from receiving an EGFR antibody such as Erbitux or Vectibix, while the remaining 40% to 50% of mCRC patients do not receive EGFR inhibitors.

Based on these statistics, Keryx estimates that only 50% to 60% of the patients to be enrolled in its upcoming Phase 3 trial for perifosine in metastatic colorectal cancer will have received and failed treatment by either Erbitux or Vectibix, which is similar to the patient population in the Keryx Phase 2 study, as well as the general population.

In summary, the pending Phase 3 study and the Phase 2 study populations will be virtually the same.

A complete report on the company is available now at BioMedReports.Com

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contact:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556